Results 91 to 100 of about 642,659 (199)

PCSK9 cellular assays.

, 2019
Addition of PCSK9 to HepG cells causes LDLR internalization. LDLR cell surface expression (A) is normalized by assigning 0% and 100% to the experiment with added and no PCSK9 respectively.
John L. Kulp III (4389241), Frank Guarnieri (2181644), Ian S. Cloudsdale (3075957), John L. Kulp Jr. (8087735)   +3 more
core   +1 more source

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

, 2023
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor.
Paweł Głuszak, Ewelina Jakielska, Wiesław Bryl, Marta Walczak   +3 more
core   +1 more source

Different blood lipid profiles and their role in cardiometabolic disease progression: A comparative study between an East Asian and European Large Prospective Cohorts

VIEW, EarlyView.
In this study, we analyzed data from the Kailuan study in China (N = 95,711) and the UK Biobank (N = 388,317), comprising adults free of CMDs at baseline. The results demonstrated distinct, population‐specific patterns regarding how blood lipids influence the transition from a healthy state to incident CMDs and subsequently to CMM.
Lili Huang, Zhe Huang, Fandi Mo, Xinming Xu, Yuchong Zhang, Xinqiang Ma, Tingting Geng, Chengkai Hu, Shiyi Li, Genmao Cao, Hanji Fang, Shouji Qiu, Zhicheng Zhang, Sun Liang, Xiang Gao, Shouling Wu, Lixin Wang   +16 more
wiley   +1 more source

New Oral Pcsk9 Inhibitor: “Mk-0616”

MK-0616, a novel oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), represents a significant advancement in the treatment of hypercholesterolemia.
Frishman, William, Siddiqui, Zoya
core   +1 more source

Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months.
Kaveh Hosseini, Hamidreza Soleimani, Saba Maleki, Amir Nasrollahizadeh, Sima Tayebi, John Nelson, Sean P. Heffron   +6 more
doaj   +1 more source

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundWe sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and ResultsWe performed a systematic review and meta‐analysis of randomized controlled trials
Aris Karatasakis, Barbara A Danek, Judit Karacsonyi, Bavana V Rangan, Michele K Roesle, Thomas Knickelbine, Michael D Miedema, Houman Khalili, Zahid Ahmad, Shuaib Abdullah, Subhash Banerjee, Emmanouil S. Brilakis   +11 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment

Journal of Lipid Research, 2013
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the LDL receptor (LDLR) at the cell surface and reroutes the internalized LDLR to intracellular degradation.
Kristian Tveten, Thea Bismo Str⊘m, Knut Erik Berge, Trond P. Leren   +3 more
doaj   +1 more source

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

British Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli, Alessia Campagna, Barbara Eramo, Christian Sepe, Annarita Zuena, Silvana Gaetani, Adele Romano   +6 more
wiley   +1 more source